BRIEF-Rigel Pharmaceuticals Inc On April 16, Received Written Notice From Eli Lilly

Eli Lilly and Company
Rigel Pharmaceuticals, Inc.

Eli Lilly and Company

LLY

0.00

Rigel Pharmaceuticals, Inc.

RIGL

0.00

April 21 (Reuters) - Eli Lilly and Co LLY.N:

  • RIGEL PHARMACEUTICALS INC: ON APRIL 16, RECEIVED WRITTEN NOTICE FROM ELI LILLY

  • RIGEL PHARMACEUTICALS INC - ELI LILLY TO TERMINATE LICENSE AND COLLABORATION AGREEMENT WITH RIGEL PHARMACEUTICALS - SEC FILING

  • RIGEL PHARMACEUTICALS INC - AGREEMENT TERMINATION EFFECTIVE JUNE 15, 2026 - SEC FILING

  • RIGEL PHARMACEUTICALS INC - TO REGAIN FULL RIGHTS TO LICENSED COMPOUNDS AFTER TERMINATION - SEC FILING

  • RIGEL PHARMACEUTICALS INC - DOES NOT EXPECT FUTURE MILESTONES OR ROYALTIES UNDER AGREEMENT AFTER TERMINATION - SEC FILING

Source text: [ID:n0001034842-26-000027]

Further company coverage: LLY.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.